# EPRX (Eupraxia Pharmaceuticals Inc.) - SEC EDGAR Financial Statements

> Eupraxia Pharmaceuticals Inc. reported $0 in revenue and a net loss of $38.58M for the fiscal year ended December 31, 2025.

- Canonical: https://convexityos.com/fundamentals/EPRX
- Markdown: https://convexityos.com/fundamentals/EPRX.md
- SEC CIK: 0001581178
- Reporting currency: USD
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:36 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001581178&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | $0 | Dec 31, 2025 |
| Operating Income | FY 2025 | -$38.43M | Operating profit |
| Net Income | FY 2025 | -$38.58M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.03 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Dec 31, 2025 | $80.56M | Total debt: $154K |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | $0 | $0 | $0 | -- |
| Research & Development | $21.33M | $16.08M | $20.36M | $13.63M |
| Total Operating Expenses | $38.43M | $27.00M | $27.85M | $17.62M |
| **Operating Income** | -$38.43M | -$27.00M | -$27.85M | -$17.62M |
| **EBITDA** | -$38.20M | -$26.83M | -$27.69M | -$17.47M |
| Interest Income | $1.41M | $1.16M | $863K | $432K |
| Interest Expense | $0 | $604K | $1.17M | $983K |
| Income Before Tax | -$38.59M | -$25.74M | -$28.93M | -$18.99M |
| Income Tax Expense | $19K | $1.8K | $36K | $0 |
| **Net Income** | -$38.58M | -$25.50M | -$28.22M | -$18.49M |
| Basic EPS | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| **Diluted EPS** | -$1.03 | -$0.76 | -$1.17 | -$0.96 |
| Basic Shares Outstanding | 40.0M | 33.9M | 24.1M | 19.3M |
| Diluted Shares Outstanding | 40.0M | 33.9M | 24.1M | 19.3M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $80.56M | $33.10M | $19.34M | $18.26M |
| **Cash & Short-Term Investments** | $80.56M | $33.10M | $19.34M | $18.26M |
| Accounts Receivable, Net | $716K | $258K | $154K | -- |
| **Total Current Assets** | $85.10M | $34.44M | $19.80M | $18.59M |
| Property, Plant & Equipment, Net | $834K | $358K | $410K | $443K |
| **Total Non-Current Assets** | $1.05M | $506K | $463K | $533K |
| **Total Assets** | $86.15M | $34.94M | $20.27M | $19.12M |
| Accounts Payable | $942K | $377K | $1.29M | $1.81M |
| **Total Current Liabilities** | $5.63M | $3.10M | $19.37M | $3.06M |
| **Total Non-Current Liabilities** | $76K | $0 | $0 | $8.86M |
| **Total Liabilities** | $5.70M | $3.10M | $19.37M | $11.91M |
| **Total Debt (incl. Leases)** | $154K | $72K | $53K | $102K |
| Common Stock | $195.4M | $116.4M | $92.91M | $71.00M |
| Retained Earnings | -$169.6M | -$131.0M | -$105.5M | -$77.28M |
| Accumulated Other Comp. Income | -$2.04M | -$4.16M | -$2.71M | -$2.79M |
| **Total Stockholders' Equity** | $82.04M | $33.40M | $2.22M | $7.79M |
| Total Equity | $80.45M | $31.84M | $892K | $7.21M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
| --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $80.56M | $33.10M | $19.34M | $18.26M |
| **Cash & Short-Term Investments** | $80.56M | $33.10M | $19.34M | $18.26M |
| Accounts Receivable, Net | $716K | $258K | $154K | -- |
| **Total Current Assets** | $85.10M | $34.44M | $19.80M | $18.59M |
| Property, Plant & Equipment, Net | $834K | $358K | $410K | $443K |
| **Total Non-Current Assets** | $1.05M | $506K | $463K | $533K |
| **Total Assets** | $86.15M | $34.94M | $20.27M | $19.12M |
| Accounts Payable | $942K | $377K | $1.29M | $1.81M |
| **Total Current Liabilities** | $5.63M | $3.10M | $19.37M | $3.06M |
| **Total Non-Current Liabilities** | $76K | $0 | $0 | $8.86M |
| **Total Liabilities** | $5.70M | $3.10M | $19.37M | $11.91M |
| **Total Debt (incl. Leases)** | $154K | $72K | $53K | $102K |
| Common Stock | $195.4M | $116.4M | $92.91M | $71.00M |
| Retained Earnings | -$169.6M | -$131.0M | -$105.5M | -$77.28M |
| Accumulated Other Comp. Income | -$2.04M | -$4.16M | -$2.71M | -$2.79M |
| **Total Stockholders' Equity** | $82.04M | $33.40M | $2.22M | $7.79M |
| Total Equity | $80.45M | $31.84M | $892K | $7.21M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -$38.61M | -$25.74M | -$28.97M | -$18.99M |
| Depreciation & Amortization | $238K | $172K | $156K | $148K |
| Stock-Based Compensation | $8.76M | $3.22M | $1.41M | $1.43M |
| Change in Receivables | -$431K | -$101K | -$104K | $230K |
| **Operating Cash Flow** | -$28.55M | -$29.99M | -$20.75M | -$14.40M |
| **Investing Cash Flow** | -$589K | -$75K | -$73K | $9.83M |
| Common Stock Issued | $73.89M | $22.85M | $15.89M | $10.64M |
| **Financing Cash Flow** | $76.06M | $45.78M | $21.08M | $10.80M |
| **Net Change in Cash** | $46.92M | $15.71M | $257K | $6.24M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -47.0% | -76.3% | -1273.4% | -237.5% |
| Return on Assets (ROA) | -44.8% | -73.0% | -139.3% | -96.7% |
| Current Ratio | 15.12x | 11.10x | 1.02x | 6.08x |
| Quick Ratio | 14.44x | 10.75x | 1.01x | 5.97x |
| Debt to Equity | 0.00x | 0.00x | 0.02x | 0.01x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
